Traders tend to overreact to some of the inside trading and forgetting the whole picture. SOMX data does has it flaws in it, but as Sheff mentioned before, they have met with FDA and know exactly what needs to be done. FDA doesnt not issue class one resubmission on CRL if a major issue is present, if they dont believe that needed fixes can be implemented in two month time frame.
Somx was due for some healthy pullback, stock cannot go up all the time. Unfortunately this pullback was rather bigger than expected.
Sleep medicine is something USA needs a lot, especially with all known issues with drugs like ambien.
IMHO, somx has really high chance for passing FDA test this time around.
GLTA
News 
Market Data 
Discover 
